Loes NissenInflammatory bowel disease (IBD) patients are frequently treated with immunosuppressive medication. These medications increase the risk to develop Epstein-Barr virus (EBV) related lymphoma’s which histologically resemble post-transplantation lymphoma’s (PTLD) and are also EBV related. We found that specific histologic aberrations in intestinal mucosa predict EBV presence and may guide EBV diagnostics, the histologic PTLD classification is also suitable for classification of IBD related lymphoproliferations and that a higher EBV load is related to colectomy in IBD. The clinical course of EBV related lymphoma’s in IBD appears less agressive than in PTLD. Furthermore, we studied solid malignancies. The studied risk factors for IBD patients to develop certain malignancies and studied the clinical course of these malignancies. The survival of gastric cancer and oral cavity cancer was impaired, but not the survival of melanoma and pharyngeal cancer. In our studies, immunosuppression use did not (negatively) influence survival, what is assuring for daily practice, but should be interpreted with very much caution.
Date, time and location PhD defense Loes Nissen
- Date: 29 May2018
- Time: 10:30 hrs
- Location: Radboud Universiteit, Academiezaal Aula, Comeniuslaan 2
Loes Nissen (1982) studied Medicine at the Radboud University Nijmegen and obtained her medical degree in 2006. The research in this thesis was performed at the Department of Gastroenterology and Hepatology and at the Department of Histopathology. Currently, she is working as a gastroenterologist at the Jeroen Bosch Ziekenhuis in Den Bosch, with special focus on inflammatory bowel diseases.
- Promotor(s): Prof. J.P.H. Drenth
- Co-promotor(s): Prof. I.D. Nagtegaal and F. Hoentjen, PhD